Unlock instant, AI-driven research and patent intelligence for your innovation.

Sample treatment method and treatment agent for tuberculosis infection T cell assay

A treatment agent and cell technology, applied in the field of biochemical reagents, can solve the problems of high gamma-interferon, affecting the interpretation and accuracy of results, etc., and achieve the effects of high content, reduced non-specific adsorption, and large amount of antibodies

Active Publication Date: 2018-08-17
广州市丰华生物股份有限公司
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a sample processing method and processing agent for the determination of T cells infected with tuberculosis, which solves the problem of non-in vitro release of gamma-interferon in previous gamma-interferon release tests. - The interferon is too high, which affects the interpretation and accuracy of the results.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sample treatment method and treatment agent for tuberculosis infection T cell assay
  • Sample treatment method and treatment agent for tuberculosis infection T cell assay
  • Sample treatment method and treatment agent for tuberculosis infection T cell assay

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] As an embodiment of the treatment agent used in the determination of tuberculosis-infected T cells described in the present invention, the treatment agent used in the determination of tuberculosis-infected T cells described in this embodiment includes magnetic beads coupled with γ-interferon antibody and a treatment agent Diluent. The diluent is 0.85% physiological saline. The mass ratio of the magnetic beads to the γ-interferon antibody is 1:0.1; the particle diameter of the magnetic beads is 1500nm.

[0041] The preparation method of the treatment agent for tuberculosis infection T cell assay described in this embodiment is:

[0042] Materials: BioMagPlus carboxyl magnetic beads with a particle size of 1.5 μm; EDAC (1-ethyl-3-3-dimethylaminopropylcarbodiimide) reagent; 15mL pointed centrifuge tube; BioMag magnetic separator; 0.05M, 2-morpholineethanesulfonic acid (MES) buffer at pH 5.2; quenching solution; and washing buffer were provided by Bangs. BSA for Componen...

Embodiment 2

[0069] As an embodiment of the treatment agent used for the determination of tuberculosis-infected T cells described in the present invention, the treatment agent used for the determination of tuberculosis-infected T cells described in this embodiment includes carboxyl magnetic beads coupled to γ-interferon antibody and treated agent diluent. The mass ratio of the magnetic beads to the γ-interferon antibody is 1:0.02. The treatment agent includes a diluent of the treatment agent, and the diluent is 0.85% physiological saline. The particle size of the magnetic beads is 5000nm.

[0070] The preparation method of the treatment agent for tuberculosis infection T cell assay described in this embodiment is:

[0071] Materials: BioMagPlus carboxyl magnetic beads with a particle size of 5.0 μm; EDAC (1-ethyl-3-3-dimethylaminopropylcarbodiimide) reagent; 15mL pointed centrifuge tube; BioMag magnetic separator; Methylsulfonic acid (MES) buffer; quenching solution; washing buffer were...

Embodiment 3

[0098] As an embodiment of the treatment agent used for the determination of tuberculosis-infected T cells described in the present invention, the treatment agent used for the determination of tuberculosis-infected T cells described in this embodiment includes carboxyl magnetic beads coupled to γ-interferon antibody and treated agent diluent. The mass ratio of the magnetic beads to the γ-interferon antibody is 1:0.5. The diluent is 0.85% physiological saline, and the particle diameter of the magnetic beads is 500nm.

[0099] The preparation method of the treatment agent for tuberculosis infection T cell assay described in this embodiment is:

[0100] Materials: BioMagPlus carboxyl magnetic beads with a particle size of 0.5 μm; EDAC (1-ethyl-3-3-dimethylaminopropylcarbodiimide) reagent; 15mL pointed centrifuge tube; BioMag magnetic separator; Methylsulfonic acid (MES) buffer; quenching solution; washing buffer were provided by Bangs. BSA for Component 5 was supplied by Roche...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a treatment agent and a sample treatment method for tuberculosis infection T cell assay. The treatment agent comprises a magnetic bead coupled with a gamma-interferon antibody,and a mass ratio of the magnetic bead to the gamma-interferon antibody is 1:(0.02-0.5). The treatment agent uses the magnetic bead as a carrier, the magnetic bead is coupled with the gamma-interferonantibody, the antibody can bind to gamma-interferon in a blood sample to form a gamma-interferon-antibody-magnetic bead compound, and the compound is separated from blood together with the magnetic bead under the action of magnetic separation in order to achieve the purpose of removing the gamma-interferon from the blood. The treatment method can treat samples in batches, is simple and rapid, andcan completely eliminate the interference of the gamma-interferon to the samples by adopting a homogeneous immunoreaction and a magnetic separation technology.

Description

technical field [0001] The invention relates to the technical field of biochemical reagents, in particular to a sample processing method and a processing agent for measuring T cells infected with tuberculosis. Background technique [0002] Interferon-gamma release assays (IGRAs) in vitro are effective methods for detecting Mycobacterium tuberculosis infection, cytomegalovirus (Cytomegaoviyns, CMV) infection and Cokelia Bainii infection, and are now mainly used clinically. Auxiliary diagnosis of Mycobacterium tuberculosis. [0003] Tuberculosis seriously endangers public safety, and 2 million people die of tuberculosis every year in the world. In China, there are 1 million new tuberculosis patients every year. When Mycobacterium tuberculosis invades the human body, the first line of defense is natural immunity. In most cases, M. tuberculosis is eliminated by innate immunity. When the number of Mycobacterium tuberculosis cells is too large, the virulence is strong, or the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N1/28G01N1/38G01N33/569C12Q1/02
CPCG01N1/28G01N1/38G01N33/5005G01N33/5695
Inventor 谭玉华王银德赵凡一毛静宜
Owner 广州市丰华生物股份有限公司